Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–2 of 2 results
Advanced filters: Author: Thomas Karasic Clear advanced filters

  • ctDNA is a known poor prognostic factor for multiple cancer types, but variant-specificity is unknown. Here, the authors show variant-specific association of ctKRAS levels with survival in previously untreated metastatic pancreatic ductal adenocarcinoma patients in multiple cohorts.

    • Jacob E. Till
    • Lee McDaniel
    • Erica L. Carpenter
    ResearchOpen Access
    Nature Communications
    Volume: 15, P: 1-12

  • In an arm of a phase 1b trial, the combination of divarasib, a KRAS G12C inhibitor, and cetuximab, an epidermal growth factor receptor inhibitor, was well tolerated with an encouraging overall response rate of 62.5% in patients with KRAS G12C-positive colorectal cancer.

    • Jayesh Desai
    • Guzman Alonso
    • Sae-Won Han
    ResearchOpen Access
    Nature Medicine
    Volume: 30, P: 271-278